These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
445 related articles for article (PubMed ID: 24185376)
1. Novel water-soluble prodrugs of acyclovir cleavable by the dipeptidyl-peptidase IV (DPP IV/CD26) enzyme. Diez-Torrubia A; Cabrera S; de Castro S; García-Aparicio C; Mulder G; De Meester I; Camarasa MJ; Balzarini J; Velázquez S Eur J Med Chem; 2013; 70():456-68. PubMed ID: 24185376 [TBL] [Abstract][Full Text] [Related]
2. Dipeptidyl peptidase IV dependent water-soluble prodrugs of highly lipophilic bicyclic nucleoside analogues. Diez-Torrubia A; Balzarini J; Andrei G; Snoeck R; De Meester I; Camarasa MJ; Velázquez S J Med Chem; 2011 Mar; 54(6):1927-42. PubMed ID: 21332170 [TBL] [Abstract][Full Text] [Related]
3. Application of the dipeptidyl peptidase IV (DPPIV/CD26) based prodrug approach to different amine-containing drugs. Diez-Torrubia A; García-Aparicio C; Cabrera S; De Meester I; Balzarini J; Camarasa MJ; Velázquez S J Med Chem; 2010 Jan; 53(2):559-72. PubMed ID: 20000418 [TBL] [Abstract][Full Text] [Related]
6. Efficient conversion of tetrapeptide-based TSAO prodrugs to the parent drug by dipeptidyl-peptidase IV (DPPIV/CD26). García-Aparicio C; Diez-Torrubia A; Balzarini J; Lambeir AM; Velázquez S; Camarasa MJ Antiviral Res; 2007 Nov; 76(2):130-9. PubMed ID: 17675255 [TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationships for dipeptide prodrugs of acyclovir: implications for prodrug design. Santos CR; Capela R; Pereira CS; Valente E; Gouveia L; Pannecouque C; De Clercq E; Moreira R; Gomes P Eur J Med Chem; 2009 Jun; 44(6):2339-46. PubMed ID: 18848738 [TBL] [Abstract][Full Text] [Related]
8. Dipeptidyl-peptidase IV (DPP IV/CD26)-activated prodrugs: a successful strategy for improving water solubility and oral bioavailability. Velázquez S; de Castro S; Diez-Torrubia A; Balzarini J; Camarasa MJ Curr Med Chem; 2015; 22(8):1041-54. PubMed ID: 25620096 [TBL] [Abstract][Full Text] [Related]
9. A new homodimer of aciclovir as a prodrug with increased solubility and antiviral activity. Brandi G; Rossi L; Schiavano GF; Millo E; Magnani M Int J Antimicrob Agents; 2009 Aug; 34(2):177-80. PubMed ID: 19394201 [TBL] [Abstract][Full Text] [Related]
10. 5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Han H; de Vrueh RL; Rhie JK; Covitz KM; Smith PL; Lee CP; Oh DM; Sadée W; Amidon GL Pharm Res; 1998 Aug; 15(8):1154-9. PubMed ID: 9706043 [TBL] [Abstract][Full Text] [Related]
11. Simultaneous modulation of transport and metabolism of acyclovir prodrugs across rabbit cornea: An approach involving enzyme inhibitors. Katragadda S; Talluri RS; Mitra AK Int J Pharm; 2006 Aug; 320(1-2):104-13. PubMed ID: 16720085 [TBL] [Abstract][Full Text] [Related]
12. Design and discovery of a novel dipeptidyl-peptidase IV (CD26)-based prodrug approach. García-Aparicio C; Bonache MC; De Meester I; San-Félix A; Balzarini J; Camarasa MJ; Velazquez S J Med Chem; 2006 Aug; 49(17):5339-51. PubMed ID: 16913724 [TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl peptidase-4 greatly contributes to the hydrolysis of vildagliptin in human liver. Asakura M; Fujii H; Atsuda K; Itoh T; Fujiwara R Drug Metab Dispos; 2015 Apr; 43(4):477-84. PubMed ID: 25597851 [TBL] [Abstract][Full Text] [Related]
15. Novel biotinylated lipid prodrugs of acyclovir for the treatment of herpetic keratitis (HK): transporter recognition, tissue stability and antiviral activity. Vadlapudi AD; Vadlapatla RK; Earla R; Sirimulla S; Bailey JB; Pal D; Mitra AK Pharm Res; 2013 Aug; 30(8):2063-76. PubMed ID: 23657675 [TBL] [Abstract][Full Text] [Related]
16. The dipeptidyl peptidase IV (CD26, EC 3.4.14.5) inhibitor vildagliptin is a potent antihyperalgesic in rats by promoting endomorphin-2 generation in the spinal cord. Király K; Lambeir AM; Szalai J; Szentirmay A; Luyten W; Barna I; Puskár Z; Kozsurek M; Rónai AZ Eur J Pharmacol; 2011 Jan; 650(1):195-9. PubMed ID: 20940010 [TBL] [Abstract][Full Text] [Related]
17. Successful kinase bypass with new acyclovir phosphoramidate prodrugs. McGuigan C; Derudas M; Bugert JJ; Andrei G; Snoeck R; Balzarini J Bioorg Med Chem Lett; 2008 Aug; 18(15):4364-7. PubMed ID: 18614365 [TBL] [Abstract][Full Text] [Related]
18. Obligatory involvement of CD26/dipeptidyl peptidase IV in the activation of the antiretroviral tripeptide glycylprolylglycinamide (GPG-NH(2)). Balzarini J; Andersson E; Schols D; Proost P; Van Damme J; Svennerholm B; Horal P; Vahlne A Int J Biochem Cell Biol; 2004 Sep; 36(9):1848-59. PubMed ID: 15183349 [TBL] [Abstract][Full Text] [Related]
19. Novel dipeptide prodrugs of acyclovir for ocular herpes infections: Bioreversion, antiviral activity and transport across rabbit cornea. Anand B; Nashed Y; Mitra A Curr Eye Res; 2003; 26(3-4):151-63. PubMed ID: 12815543 [TBL] [Abstract][Full Text] [Related]
20. Discovery of C-(1-aryl-cyclohexyl)-methylamines as selective, orally available inhibitors of dipeptidyl peptidase IV. Namoto K; Sirockin F; Ostermann N; Gessier F; Flohr S; Sedrani R; Gerhartz B; Trappe J; Hassiepen U; Duttaroy A; Ferreira S; Sutton JM; Clark DE; Fenton G; Beswick M; Baeschlin DK Bioorg Med Chem Lett; 2014 Feb; 24(3):731-6. PubMed ID: 24439847 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]